Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel P. Cahill, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Daniel Cahill and Hiroaki Wakimoto.
Connection Strength

4.444
  1. Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma. Cancer Res. 2021 Apr 01; 81(7):1922.
    View in: PubMed
    Score: 0.239
  2. Sirtuin activation targets IDH-mutant tumors. Neuro Oncol. 2021 01 30; 23(1):53-62.
    View in: PubMed
    Score: 0.236
  3. Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma. Cancer Res. 2020 11 15; 80(22):5024-5034.
    View in: PubMed
    Score: 0.231
  4. Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. Cancer Discov. 2020 11; 10(11):1672-1689.
    View in: PubMed
    Score: 0.227
  5. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Clin Cancer Res. 2020 04 01; 26(7):1690-1699.
    View in: PubMed
    Score: 0.219
  6. A Monoclonal Antibody Against ß1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. Target Oncol. 2019 08; 14(4):479-489.
    View in: PubMed
    Score: 0.213
  7. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 07 15; 25(14):4375-4387.
    View in: PubMed
    Score: 0.209
  8. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep. 2019 01 15; 9(1):139.
    View in: PubMed
    Score: 0.205
  9. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. . 2018 12; 17(12):2551-2563.
    View in: PubMed
    Score: 0.200
  10. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394.
    View in: PubMed
    Score: 0.199
  11. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017 Dec 12; 8(65):109228-109237.
    View in: PubMed
    Score: 0.190
  12. IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy. Neurosurgery. 2017 09 01; 64(CN_suppl_1):134-138.
    View in: PubMed
    Score: 0.187
  13. Blockade of transforming growth factor-ß signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017 12 01; 141(11):2348-2358.
    View in: PubMed
    Score: 0.186
  14. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res. 2017 08 01; 77(15):4102-4115.
    View in: PubMed
    Score: 0.184
  15. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res. 2016 Sep 01; 22(17):4452-65.
    View in: PubMed
    Score: 0.169
  16. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol. 2016 09; 18(9):1278-87.
    View in: PubMed
    Score: 0.168
  17. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015 Dec 14; 28(6):773-784.
    View in: PubMed
    Score: 0.166
  18. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014 Jun 01; 20(11):2898-909.
    View in: PubMed
    Score: 0.147
  19. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26.
    View in: PubMed
    Score: 0.059
  20. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020 10 21; 8(1):171.
    View in: PubMed
    Score: 0.058
  21. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. Cancer Res. 2020 12 01; 80(23):5330-5343.
    View in: PubMed
    Score: 0.058
  22. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 2020 08 20; 9(1):1806662.
    View in: PubMed
    Score: 0.057
  23. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.056
  24. Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathol. 2020 07; 140(1):89-93.
    View in: PubMed
    Score: 0.056
  25. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. Neuro Oncol. 2019 11 04; 21(11):1401-1411.
    View in: PubMed
    Score: 0.054
  26. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019 09; 37(9):1049-1058.
    View in: PubMed
    Score: 0.053
  27. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 08 08; 178(4):835-849.e21.
    View in: PubMed
    Score: 0.053
  28. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. Clin Cancer Res. 2019 06 01; 25(11):3374-3383.
    View in: PubMed
    Score: 0.052
  29. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma. Clin Cancer Res. 2019 02 15; 25(4):1261-1271.
    View in: PubMed
    Score: 0.051
  30. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018 11; 136(5):779-792.
    View in: PubMed
    Score: 0.050
  31. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer Cell. 2017 10 09; 32(4):411-426.e11.
    View in: PubMed
    Score: 0.047
  32. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 03 31; 355(6332).
    View in: PubMed
    Score: 0.045
  33. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell. 2017 02 02; 20(2):233-246.e7.
    View in: PubMed
    Score: 0.044
  34. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun 20; 344(6190):1396-401.
    View in: PubMed
    Score: 0.037
  35. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014 Apr 24; 157(3):580-94.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.